Global Tuberculosis Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Therapy Type;
First Line Drug therapy - Isoniazid, Rifampicin, Ethambutol, Pyrazinamide and Streptomycin, Second Line Drugs Therapy - Bedaquiline, Fluoroquinolones, Bacteriostatic Agents and Others, and Combination Drug Therapy.By Disease Type;
Pulmonary Tuberculosis and Extrapulmonary Tuberculosis.By Dosage Form;
Tablets, Capsules, Injection, and Others.By Distribution Channel;
Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Tuberculosis Therapeutics Market (USD Million), 2021 - 2031
In the year 2024, the Global Tuberculosis Therapeutics Market was valued at USD 2,896.35 million. The size of this market is expected to increase to USD 3,702.44 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.6%.
The global tuberculosis (TB) therapeutics market is a critical segment of the pharmaceutical industry, focused on addressing one of the world's most persistent infectious diseases. Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, primarily affects the lungs but can also impact other parts of the body. Despite significant advances in medical science and public health, TB remains a major global health challenge, particularly in low- and middle-income countries. The World Health Organization (WHO) has identified TB as one of the top 10 causes of death worldwide, highlighting the urgent need for effective treatments and the continued development of innovative therapeutics.
The market for TB therapeutics is driven by several key factors, including the high prevalence of the disease, the emergence of drug-resistant strains, and the concerted efforts of global health organizations to combat TB. Traditional TB treatment regimens typically involve a combination of antibiotics over a period of six to nine months, which can be challenging for patients to complete, leading to issues with adherence and the development of resistance. Consequently, there is a significant demand for new drugs that can shorten treatment duration, improve efficacy, and reduce side effects, thereby enhancing patient compliance and outcomes.
Technological advancements and increased funding for research and development are also pivotal in shaping the TB therapeutics market. Innovative approaches, such as the development of new drug classes, the use of novel drug delivery systems, and the exploration of adjunctive therapies, are being actively pursued. Moreover, the integration of digital health technologies to monitor and support treatment adherence is gaining traction, offering promising avenues for improving the management of TB. Partnerships between pharmaceutical companies, academic institutions, and non-governmental organizations are crucial in driving these advancements and ensuring that new treatments are accessible to those in need.
Despite these advancements, the TB therapeutics market faces several challenges. The lengthy and costly process of drug development, regulatory hurdles, and the need for comprehensive clinical trials can impede the introduction of new treatments. Additionally, socio-economic factors, including healthcare infrastructure and access to medical services in resource-limited settings, play a significant role in the effectiveness of TB control efforts. Addressing these challenges requires a multi-faceted approach, involving not only scientific and medical innovations but also policy support and international collaboration to ensure that progress in TB therapeutics translates into tangible health improvements globally.
Global Tuberculosis Therapeutics Market Recent Developments
-
2020, GlaxoSmithKline (GSK), which has a TB drug development program focused on developing drugs that are effective against drug-resistant TB. GSK is currently testing a drug called GSK3036656 in clinical trials, which has shown promise in early studies.
-
2019, Otsuka Pharmaceutical Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for a new TB drug, Pretomanid, for the treatment of extensively drug-resistant TB.
-
2019, the US Food and Drug Administration (FDA) approved a new drug called pretomanid. Pretomanid is part of a three-drug regimen called BPaL, which also includes bedaquiline and linezolid, that has been shown to be highly effective in treating highly drug-resistant forms of TB. In a phase Ill trial conducted in South Africa, the BPaL regimen cured 90% of patients with extensively drug-resistant TB, a form of TB that is resistant to at least four of the main TB drugs. The BPaL regimen is also shorter than the previous standard of care for drug-resistant TB, taking just six months instead of up to two years.
Segment Analysis
Therapy Type segmentation focuses on the different approaches to treating tuberculosis, which include Antibiotic Therapy, Combination Therapy, and Supportive Therapy. Antibiotic therapy is the most common treatment for TB and involves a combination of drugs, such as isoniazid, rifampicin, pyrazinamide, and ethambutol, administered over a course of six to nine months. This regimen is aimed at eradicating the bacteria and preventing the development of drug resistance. Combination therapy is often utilized to improve efficacy and reduce the likelihood of resistance, employing multiple drugs with different mechanisms of action. Supportive therapy, which includes treatments like nutritional support and adjunctive medications, helps manage symptoms and enhance overall patient well-being during TB treatment. The growing demand for effective and efficient therapy options, including drug-resistant TB treatments, has driven research into new medications and combination therapy regimens.
Disease Type segmentation in the TB therapeutics market differentiates between Active TB and Latent TB. Active TB is the contagious form of the disease, where bacteria multiply and cause symptoms such as chronic cough, chest pain, and fever. This requires prompt, intensive treatment to prevent transmission and complications. Latent TB is asymptomatic and non-contagious but can progress to active TB if the immune system weakens. Therapeutic approaches for latent TB focus on preventing reactivation through shorter courses of preventive antibiotics. The segmentation helps guide the development of targeted therapies and strategies to manage both active and latent TB cases effectively.
Form segmentation refers to the different physical forms of TB drugs, including Tablets, Injectables, and Injectable Solutions. Tablets are the most common form, preferred for ease of administration and widespread use. Injectables, often used for intensive initial treatment phases or drug-resistant TB cases, provide a more direct method of delivering medications to the bloodstream for quick action. Injectable solutions are particularly valuable in hospital settings for immediate administration and treatment of severe cases, ensuring precise dosing and rapid response.
Distribution Channel segmentation in the TB therapeutics market encompasses Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospital pharmacies are key distribution points for TB medications, especially for inpatients and severe cases, where specialized treatment regimens are managed by healthcare professionals. Retail pharmacies provide TB medications to outpatients and individuals managing chronic cases, ensuring that patients can access their prescriptions conveniently. The role of online pharmacies has been expanding, driven by the increasing demand for remote healthcare services and home delivery options. However, regulatory compliance and safety concerns are crucial for ensuring the authenticity and proper handling of TB medications through online channels.
Geography segmentation in the TB therapeutics market considers the regional distribution and market dynamics across various parts of the world. The market varies significantly by region due to differences in TB prevalence, healthcare infrastructure, economic conditions, and government policies. High-burden countries, such as India, China, and South Africa, drive a substantial portion of the market due to their higher TB incidence rates and ongoing public health initiatives aimed at combating the disease. The market in developed regions may focus more on advanced therapies, drug-resistant TB treatment, and research initiatives, while emerging markets may prioritize affordable, accessible treatment options to address widespread TB cases.
Global Tuberculosis Therapeutics Segment Analysis
In this report, the Global Tuberculosis Therapeutics Market has been segmented by Therapy Type, Disease Type, Dosage Form, Distribution Channel, and Geography.
Global Tuberculosis Therapeutics Market, Segmentation by Therapy Type
The Global Tuberculosis Therapeutics Market has been segmented by Therapy Type into First Line Drugs Therapy, Second Line Drugs Therapy and Combination Drug Therapy.
First Line Drugs Therapy is the initial and most commonly used approach for treating tuberculosis. This therapy includes a combination of drugs such as Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide. These medications are highly effective against Mycobacterium tuberculosis, the bacterium responsible for TB, particularly in drug-susceptible cases. The effectiveness of first-line drugs is well-documented, and they are typically administered over a period of six to nine months. This therapy aims to eradicate the infection while minimizing the risk of developing drug resistance, making it the cornerstone of TB treatment protocols globally.
Second Line Drugs Therapy is employed when the tuberculosis strain is resistant to first-line drugs, a condition known as multi-drug resistant TB (MDR-TB). Second line drugs include fluoroquinolones (e.g., Levofloxacin, Moxifloxacin) and injectable agents (e.g., Amikacin, Kanamycin, Capreomycin). These drugs are often more expensive, have a longer treatment duration, and can cause more severe side effects compared to first-line drugs. Despite these challenges, second line drugs are crucial for treating MDR-TB and preventing the spread of drug-resistant strains.
Combination Drug Therapy involves the use of both first line and second line drugs, often tailored to the specific needs of the patient. This approach is particularly important for patients with extensively drug-resistant TB (XDR-TB) or those with co-infections such as HIV. By combining multiple drugs with different mechanisms of action, this therapy aims to enhance efficacy and reduce the likelihood of drug resistance. The development of new combination therapies is a focus of ongoing research, driven by the need for more effective treatments and better patient outcomes.
Global Tuberculosis Therapeutics Market, Segmentation by Disease Type
The Global Tuberculosis Therapeutics Market has been segmented by Disease Type into Pulmonary Tuberculosis and Extrapulmonary Tuberculosis.
Pulmonary tuberculosis primarily affects the lungs. It is the most common form of tuberculosis and is typically associated with symptoms such as persistent cough, chest pain, and coughing up blood. Diagnosis of pulmonary tuberculosis often involves tests such as Mantoux tuberculin skin test (TST), TB blood test, and chest radiography to detect chest abnormalities. The treatment for drug-susceptible pulmonary TB disease traditionally involves the use of four drugs: isoniazid (INH), rifampin (RIF), ethambutol (ETH), and pyrazinamide (PZA)
Extrapulmonary Tuberculosis: Extrapulmonary tuberculosis affects parts of the body other than the lungs. It can manifest in various forms, such as lymph node tuberculosis, bone and joint tuberculosis, genitourinary tuberculosis, and others. Diagnosis of extrapulmonary tuberculosis may involve a combination of immunologic responses to provocative tests, radiology, microbiology, molecular methods, and biomarkers to establish a diagnosis. The increasing prevalence of multi-drug resistant (MDR) tuberculosis globally is one of the key factors driving the growth of the market for tuberculosis therapeutics.
Global Tuberculosis Therapeutics Market, Segmentation by Dosage Form
The Global Tuberculosis Therapeutics Market has been segmented by Dosage Form into Tablets, Capsules, Injection, and Others.
Tablets are among the most common and widely used dosage forms due to their convenience, cost-effectiveness, and ease of storage. They are solid, easy to manufacture, and can be formulated to release the drug at specific rates, providing controlled or extended-release options. Tablets are suitable for a wide range of treatments, including chronic conditions like hypertension and diabetes, as well as acute illnesses. Their popularity is driven by their ease of use, ability to be divided or crushed if necessary, and a relatively long shelf life.
Capsules offer another popular oral dosage form, distinguishing themselves from tablets by their gel or hard-shell structure, which can encase either a liquid, powder, or a combination of active ingredients. Capsules are often preferred for their ability to mask unpleasant tastes and to allow for controlled release of medication. They are also easier to swallow for patients who have difficulty with tablets. The market for capsules has been expanding, particularly for drugs that require rapid dissolution or targeted delivery, as the gelatin shell can be modified to meet specific therapeutic requirements.
Injection is a dosage form used for administering drugs directly into the bloodstream, muscle, or under the skin, ensuring rapid absorption and immediate effect. This form is particularly essential for drugs that cannot be taken orally due to poor absorption in the digestive tract or when a quick response is needed, such as in emergency situations or for vaccines. Injections are widely used for treatments related to chronic diseases, such as diabetes (insulin injections), as well as for biologics, monoclonal antibodies, and vaccines. The growth of the injection market is fueled by advancements in delivery technologies, such as pre-filled syringes and autoinjectors, which enhance patient convenience and reduce administration errors.
Others include dosage forms such as topical creams, ointments, patches, sublingual tablets, and liquid solutions. These forms are suitable for specific treatment applications where targeted or localized drug delivery is required. Topical forms are commonly used for dermatological conditions, while sublingual tablets and oral solutions offer faster absorption for drugs that need quick systemic effects. Transdermal patches provide sustained drug release over an extended period, making them ideal for managing chronic pain or hormone therapy. The variety within the "Others" category enables pharmaceutical companies to address a wide range of patient needs and therapeutic objectives, contributing to personalized treatment plans and improving patient adherence.
Global Tuberculosis Therapeutics Market, Segmentation by Distribution Channel
The Global Tuberculosis Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.
Hospital Pharmacy is a crucial distribution channel within the healthcare system, primarily serving patients receiving treatment in hospital settings. These pharmacies are typically staffed by professional pharmacists who provide medications prescribed by hospital physicians, ensuring that patients receive the appropriate dosage and instructions for use. Hospital pharmacies also play a critical role in preparing and dispensing specialized medications, such as injectable drugs or compounded formulations, that are needed for inpatient care. The demand for hospital pharmacies has been increasing due to a rise in hospital admissions and a growing emphasis on comprehensive patient care, which includes the proper administration of medications as part of the treatment protocol.
Retail Pharmacy is one of the most common and widely recognized channels for pharmaceutical distribution. These pharmacies can be standalone stores, part of supermarket chains, or located within shopping centers, and they provide over-the-counter (OTC) medications as well as prescription drugs. Retail pharmacies serve as the primary point of contact for consumers who require medications for common ailments, chronic disease management, and preventive care. With the increasing focus on health and wellness, retail pharmacies are evolving to offer services like immunizations, health screenings, and medication therapy management, enhancing their role in supporting community health. The sector is expected to continue growing as people seek convenient, accessible healthcare options.
Online Pharmacy has emerged as a significant distribution channel, driven by advances in digital technology and changing consumer preferences. Online pharmacies allow patients to order prescription and OTC medications from the comfort of their homes, making it especially appealing for those with mobility issues or those living in remote areas. These platforms offer the advantage of home delivery and often feature user-friendly interfaces that facilitate the ordering process. The rise of online pharmacies has been further fueled by the COVID-19 pandemic, which accelerated the adoption of telemedicine and online healthcare services. However, the growth of this channel also raises concerns related to regulatory standards, ensuring the safety and authenticity of medications sold online, and safeguarding against fraudulent practices.
Global Tuberculosis Therapeutics Market, Segmentation by Geography
In this report, the Global Tuberculosis Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Tuberculosis Therapeutics Market Share (%), by Geographical Region, 2024
North America represents a significant segment in the Global Tuberculosis (TB) Therapeutics Market, driven by advanced healthcare infrastructure, high healthcare expenditure, and strong governmental and non-governmental support for TB control and prevention. The United States and Canada are the key contributors to this region, with extensive research and development activities and the presence of major pharmaceutical companies. Additionally, public awareness campaigns and rigorous screening programs contribute to the detection and treatment of TB, further fueling market growth.
In Europe, the Tuberculosis Therapeutics Market is characterized by substantial investments in healthcare systems and robust regulatory frameworks. Countries such as Germany, the United Kingdom, and France lead the market due to their well-established healthcare services and access to innovative TB treatments. The European region also benefits from collaborative efforts between countries to combat TB, supported by organizations such as the European Centre for Disease Prevention and Control (ECDC). The high prevalence of multi-drug-resistant TB in Eastern Europe further drives the demand for advanced therapeutics.
The Asia Pacific region is a major market for TB therapeutics, driven by high TB incidence rates and increasing healthcare access. Countries such as India, China, and Indonesia are significant contributors due to their large populations and high burden of TB cases. Government initiatives and international partnerships, such as those with the World Health Organization (WHO), play a crucial role in addressing TB in this region. Efforts to improve diagnostic capabilities and expand treatment coverage are ongoing, which positively impacts the market. Additionally, the rising investment in healthcare infrastructure and growing pharmaceutical industry in Asia Pacific enhance the market potential.
The Middle East and Africa region presents a unique market landscape for TB therapeutics, characterized by varying levels of healthcare development and TB prevalence. Sub-Saharan Africa, in particular, faces a high burden of TB, often compounded by the prevalence of HIV/AIDS, which necessitates comprehensive treatment approaches. Efforts by international organizations and governments to improve TB management and treatment access are crucial in this region. In the Middle East, countries like Saudi Arabia and the UAE are investing in healthcare infrastructure and public health initiatives to address TB challenges, thereby contributing to market growth.
Latin America exhibits moderate growth in the TB therapeutics market, influenced by diverse healthcare systems and varying TB incidence rates across the region. Brazil, Mexico, and Argentina are key markets due to their significant healthcare infrastructure and government efforts to control TB. Regional collaborations and support from global health organizations aid in enhancing TB treatment programs. The focus on improving diagnostic tools and expanding treatment options is critical in addressing the TB burden in this region. Public health campaigns and increasing awareness about TB prevention and treatment also play a vital role in market development.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Tuberculosis Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers
- Increasing TB prevalence worldwide
- Advancements in diagnostic tools
- Government funding initiatives
-
Rising healthcare expenditure: The global tuberculosis (TB) therapeutics market has witnessed substantial growth in recent years, owing to various factors, with rising healthcare expenditure playing a significant role. Governments and healthcare organizations worldwide are increasingly allocating budgets to combat TB, a highly contagious infectious disease that poses a significant public health threat. With a greater focus on TB prevention, diagnosis, and treatment, there has been a surge in investments in research and development aimed at developing more effective therapeutics. This increased spending has propelled the expansion of the TB therapeutics market, leading to the development of innovative drugs and treatment regimens.
The rising healthcare expenditure has facilitated the adoption of advanced diagnostic technologies and treatment modalities for TB. Rapid advancements in medical technology have enabled the development of more accurate and efficient diagnostic tests for TB, allowing for early detection and treatment initiation. Additionally, healthcare systems have been investing in the implementation of comprehensive TB control programs, which include measures such as improved access to healthcare services, increased awareness campaigns, and better infrastructure for TB diagnosis and treatment. These efforts have contributed to the overall growth of the TB therapeutics market by enhancing the efficiency and effectiveness of TB management strategies.
The growing healthcare expenditure has led to increased access to TB therapeutics, particularly in low- and middle-income countries where the burden of TB is highest. Efforts to expand healthcare coverage and improve healthcare infrastructure have resulted in greater availability of TB drugs and treatment services, thereby driving market growth. Additionally, initiatives by governments, non-profit organizations, and pharmaceutical companies to provide affordable or subsidized TB medications to underserved populations have further facilitated market expansion. Overall, the rising healthcare expenditure has played a crucial role in driving the growth of the global TB therapeutics market, with investments in research, technology, and healthcare infrastructure contributing to improved TB management and outcomes worldwide.
Restraints
- Drug resistance challenges
- High treatment costs
- Limited awareness programs
-
Regulatory hurdles: The global tuberculosis therapeutics market faces significant regulatory hurdles that can impact the development, approval, and distribution of new drugs and treatments. One major challenge is the lengthy and complex regulatory approval process required for new tuberculosis drugs. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent requirements for demonstrating safety and efficacy in clinical trials. These trials can take years to complete and require substantial financial investment from pharmaceutical companies.
Regulatory hurdles may arise from the global nature of tuberculosis and varying standards of care and regulatory frameworks across different countries. Drugs that are approved in one country may face additional requirements or delays in approval in others, leading to challenges in accessing treatments for patients worldwide. Harmonizing regulatory standards and streamlining approval processes across regions could help facilitate faster access to new tuberculosis therapeutics.
The emergence of drug-resistant strains of tuberculosis further complicates regulatory efforts. Developing treatments for drug-resistant tuberculosis requires innovative approaches and may necessitate special regulatory pathways to expedite approval. Regulatory agencies need to balance the need for rigorous evaluation of new drugs with the urgent public health need to address drug-resistant tuberculosis. Collaboration between regulators, researchers, and pharmaceutical companies is essential to overcome these regulatory hurdles and accelerate the development and approval of effective tuberculosis therapeutics.
Opportunities
- Emerging markets potential
- New drug developments
- Public-private partnerships
-
Technological innovations: In recent years, the global tuberculosis (TB) therapeutics market has witnessed significant technological innovations aimed at enhancing treatment outcomes and patient care. One notable advancement is the development of novel drug delivery systems that improve the efficacy and bioavailability of anti-TB medications. These systems, such as microparticles, nanoparticles, and liposomal formulations, help overcome challenges like poor drug solubility and systemic toxicity. By delivering drugs directly to the site of infection and ensuring sustained release, these innovations contribute to better treatment adherence and reduced side effects, ultimately enhancing the effectiveness of TB therapy.
Molecular diagnostic technologies have revolutionized TB diagnosis and personalized treatment strategies. Rapid molecular tests, such as nucleic acid amplification assays and whole-genome sequencing, enable prompt detection of TB pathogens and identification of drug resistance mutations. This allows healthcare providers to initiate appropriate treatment regimens more quickly, reducing the risk of disease transmission and improving patient outcomes. Furthermore, advancements in point-of-care testing devices have facilitated TB diagnosis in resource-limited settings, where access to laboratory infrastructure is limited. These innovations not only aid in early detection but also play a crucial role in monitoring treatment response and guiding therapeutic decisions throughout the course of TB treatment.
The integration of artificial intelligence (AI) and machine learning algorithms into TB therapeutics research has accelerated drug discovery and development processes. By analyzing vast amounts of biological and clinical data, AI algorithms can identify novel drug targets, predict drug efficacy, and optimize treatment regimens. This data-driven approach enables researchers to expedite the identification of promising drug candidates and streamline the drug development pipeline. Furthermore, AI-powered decision support systems assist healthcare providers in tailoring treatment plans to individual patient characteristics, optimizing drug dosing, and minimizing the risk of adverse reactions. Overall, technological innovations in TB therapeutics hold great promise for improving treatment outcomes, reducing the global burden of TB, and ultimately achieving the goal of TB elimination.
Competitive Landscape Analysis
Key players in Global Tuberculosis Therapeutics Market include:
- Otsuka Pharmaceutical Co., Ltd
- Novartis AG
- Lupin Pharmaceuticals, Inc
- Pfizer Inc
- Sanofi
- Bayer AG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Johnson & Johnson
- Macleods Pharmaceuticals Limited
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Dosage Form
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Global Tuberculosis Therapeutics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing TB prevalence worldwide
- Advancements in diagnostic tools
- Government funding initiatives
- Rising healthcare expenditure
- Restraints
- Drug resistance challenges
- High treatment costs
- Limited awareness programs
- Regulatory hurdles
- Opportunities
- Emerging markets potential
- New drug developments
- Public-private partnerships
- Technological innovations
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Tuberculosis Therapeutics Market, By Therapy Type , 2021 - 2031 (USD Million)
- First Line Drugs Therapy
- Isoniazid
- Rifampicin
- Ethambutol
- Pyrazinamide
- Streptomycin
- Second Line Drugs Therapy
- Bedaquiline
- Fluoroquinolones
- Bacteriostatic Agents
- Others
- Combination Drug Therapy
- First Line Drugs Therapy
- Global Tuberculosis Therapeutics Market, By Disease Type , 2021 - 2031 (USD Million)
- Pulmonary Tuberculosis
- Extrapulmonary Tuberculosis
- Global Tuberculosis Therapeutics Market, By Dosage Form, 2021 - 2031 (USD Million)
- Tablets
- Capsules
- Injection
- Others
- Global Tuberculosis Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Tuberculosis Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Tuberculosis Therapeutics Market, By Therapy Type , 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Otsuka Pharmaceutical Co., Ltd
- Novartis AG
- Lupin Pharmaceuticals, Inc
- Pfizer Inc
- Sanofi
- Bayer AG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Johnson & Johnson
- Macleods Pharmaceuticals Limited
- Company Profiles
- Analyst Views
- Future Outlook of the Market